A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia

Human Psychopharmacology

Volumn 29, Issue 1, 2014, Pages 83-88

  Suzuki, Hidenobu ^a   Gen, Keishi ^b   Takahashi, Yuki ^c  

^a Suzuki Clinic   (Japan)

^b Seimo Hospital   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

efficacy; intramuscular haloperidol; intramuscular levomepromazine; intramuscular olanzapine; safety

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HALOPERIDOL; LEVOMEPROMAZINE; MOOD STABILIZER; OLANZAPINE; PALIPERIDONE; RISPERIDONE; VALPROIC ACID;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGITATION; AGITATION CALMNESS EVALUATION SCALE; AKATHISIA; ARTICLE; BARNES AKATHISIA SCALE; DRUG EFFICACY; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOMS SCALE; DRUG SAFETY; DYSKINESIA; DYSTONIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PULSE RATE; SCHIZOPHRENIA; TREMOR;

EFFICACY; INTRAMUSCULAR HALOPERIDOL; INTRAMUSCULAR LEVOMEPROMAZINE; INTRAMUSCULAR OLANZAPINE; SAFETY;

ACUTE DISEASE; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; METHOTRIMEPRAZINE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84892596984     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2376     Document Type: Article

References (31)

1. Allen MH, Currier GW, Carpenter D, et al., 2005. Expert consensus panel for behavioral emergencies 2005. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 11: 5-108.
2. American Psychiatric Association. 2004. Practice Guidelines for the Treatment of Patients with Schizophrenia, 2nd edn. American Psychiatric Publishing, Inc.: Arlington, Virginia.
3. Barnes TRE,. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Bergstrom RF, Mitchell M, Jewell H, Richards J, McEwan J, Hatcher B,. 1999. Examination of the safety, tolerance and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects. Schizophr Res 36: 305-306.
5. Bieniek SA, Ownby RL, Penalver A, Dominguez RA,. 1998. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 18: 57-62.
6. Binder RL, McNiel DE,. 1999. Emergency psychiatry: contemporary practices in managing acutely violent patients in 20 psychiatric emergency rooms. Psychiatr Serv 50: 1553-1554.
7. Buckley NA, Sanders P,. 2000. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 23: 215-228.
8. Casey DE,. 1995. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 10: 105-114.
9. Gjerden P, Slordal L, Bramness JG,. 2010. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. Eur J Clin Pharmacol 66: 911-917.
10. Green B, Pettit T, Faith L, Seaton K,. 2004. Focus on levomepromazine. Curr Med Res Opin 20: 1877-1881.
11. Hatta K, Takahashi T, Nakamura H, et al., 1998. A risk for obstruction of the airways in the parenteral use of levomepromazine with benzodiazepine. Pharmacopsychiatry 31: 126-130.
12. Hsu WY, Huang SS, Lee BS, Chiu NY,. 2010. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 30: 230-234.
13. Inada T, 1996. Evaluation and diagnosis of drug-induced extrapyramidal symptoms. In Commentary on the DIEPSS and Guide to Its Usage., Yagi G, (eds). Seiwa Publishers: Tokyo; 11-60.
14. Kay SR, Sevy S,. 1990. Pyramidical model of schizophrenia. Schizophr Bull 16: 537-545.
15. Kay SR, Fiszbein A, Opler LA,. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
16. Keck PE Jr, Pope HG Jr., Cohen BM, McElroy SL, Nierenberg AA,. 1989. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 46: 914-918.
17. Krakowski M, Czobor P,. 1997. Violence in psychiatric patients: the role of psychosis, frontal lobe impairment, and ward turmoil. Compr Psychiatry 38: 230-236.
18. Kudo S, Ishizaki T,. 1999. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37: 435-456.
19. MacDonald K, Wilson M, Minassian A, et al.,. 2012. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol 32: 317-322.
20. McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD,. 2011. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol 26: 422-433.
21. Ono H, Tanaka K, Nishimura Y, et al., 2008. A study examining pharmacokinetics of rapid acting intra-muscular olanzapine in Japanese agitated patients with schizophrenia-rapid acting intra-muscular olanzapine phase Ib study. Jpn Clin Psychopharmacol 11: 477-489.
22. Ozeki Y, Fujii K, Kurimoto N, et al., 2010. QTc prolongation and antipsychotic QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34: 401-405.
23. Perrin E, Anand E, Dyachkova Y, Wagner T, Frediani S, Ballerini A, OBS-IM investigators group. 2012. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania. Eur Psychiatry 27: 234-239.
24. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH,. 2000. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355: 1048-1052.
25. Rush JA,. 2000. Handbook of Psychiatric Measures. American Psychiatric Association: Washington, DC; 166-168.
26. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN,. 2008. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 69: 1869-1879.
27. Schaffer CB, Shahid A, Javaid JI, Dysken MW, Davis JM,. 1982. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 2: 274-277.
28. Sharif ZA,. 1998. Common treatment goals of antipsychotics: acute treatment. J Clin Psychiatry 59: 5-8.
29. Sivaraman P, Rattehalli RD, Jayaram MB,. 2010. Levomepromazine for schizophrenia. Cochrane Database Syst Rev 10: CD007779.
30. Suzuki Y, Ono S, Sugai T, et al.,. 2011. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum Psychopharmacol 26: 440-443.
31. Wilson MP, Pepper D, Currier GW, Holloman GH Jr., Feifel D,. 2012. The psychopharmacology of agitation: consensus statement of the American association for emergency psychiatry project beta psychopharmacology workgroup. West J Emerg Med 13: 26-34.